Telo Genomics Corp (TSE:TELO) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Telo Genomics Corp has revealed promising results for its TeloViewSMM prognostic test, which outperformed existing models in identifying high and low-risk smoldering myeloma patients. This innovative test could transform patient management by offering a non-invasive method to monitor disease progression, addressing a significant market opportunity.
For further insights into TSE:TELO stock, check out TipRanks’ Stock Analysis page.